Korean startup D&C biotechnology announced winning the CES Innovation Award for the second consecutive year with their home urine diagnostic solution, ‘URINE CHECK-ER’ in 2024. The CES Innovation Award, presented by the Consumer Technology Association (CTA), is a prestigious recognition for technologically innovative products in the global consumer technology industry. This year, the company particularly drew attention by winning in the ‘Product in support of Human Security’ category.

The award-winning ‘URINE CHECK-ER’ is a next-generation home healthcare urine diagnostic solution that enables users to easily conduct urine tests at home. Maximizing user convenience, the device provides precise diagnostics, disease identification, personalized medical institution connections, and telemedicine services in one platform. Users can review test results through a dedicated application and instantly connect with medical facilities for follow-up consultations if needed.

Incorporating the Flexible Optical Bio Sensor technology from their previously CES 2024 Digital Health Innovation Award-winning ‘URINE CHECK-IT’ medical urinalysis analyzer, the solution offers medical-grade accuracy in home testing. The technology, which received the NET New Excellent Technology certification this year, ensures reliable test results and enables quick, accurate disease diagnosis and appropriate subsequent actions.

CEO Sung-soo Park expressed, “We are incredibly proud and honored to win the CES Innovation Award for the second consecutive year. It’s significant that our urine diagnostic solution has been recognized globally for its innovation and technological prowess.” He further shared their vision of continuously striving to protect people’s safe and healthy lives through their innovative technologies.
The innovative ‘URINE CHECK-ER’ will be showcased at the CES 2025 exhibition in Las Vegas from January 7th to 10th, 2024.